Clinical Trials Logo

Wegener's clinical trials

View clinical trials related to Wegener's.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT01405807 Recruiting - Vasculitis Clinical Trials

Alemtuzumab for ANCA Associated Refractory Vasculitis

ALEVIATE
Start date: February 2011
Phase: Phase 4
Study type: Interventional

Overview: This open label, randomized, multi-centre study will enroll and treat 24 patients with refractory AAV. Aims: To determine the clinical response and severe adverse event rates associated with alemtuzumab therapy among patients with relapsing or refractory ANCA associated vasculitis (AAV). Hypothesis: Treatment with alemtuzumab induces sustained remission in AAV and will reduce immunosuppressive and steroid exposure.